Menu
Menu
Introduction: Zydus Lifesciences Ltd has accomplished a significant milestone with the final approval from the United States Food and Drug Administration (USFDA) for its typical model of Paliperidone prolonged-release capsules, […]
Lupin Pharmaceuticals faces a significant moment as its Pune biotech facility receives five observations from the FDA during a recent pre-approval inspection. While this poses regulatory challenges, the company continues to showcase robust financial growth, with a 76% increase in net profit. In this post, we delve into the implications of the FDA's findings, Lupin's strategies for addressing these issues, and what it means for investors and the future of its biotech products
Alembic Pharmaceuticals has achieved a major milestone with the FDA approval of its Alcaftadine Ophthalmic Solution, designed to relieve itchy eyes caused by common allergens. This new product positions Alembic to strengthen its presence in the ophthalmic market, alongside a solid financial performance that highlights the company's growth potential. Explore the implications of this approval and what it means for allergy sufferers and the pharmaceutical industry.
AstraZeneca Pharma’s stock experienced a remarkable 12% surge after the approval of Durvalumab (Imfinzi) for treating non-small cell lung cancer in India. This key regulatory milestone opens new avenues for the company in the oncology market, reflecting growing investor confidence in its innovative therapies. Explore the implications of this approval and what it means for AstraZeneca’s future.
Strides Pharma Science Ltd's subsidiary has achieved a significant milestone with the USFDA’s approval of its generic Fluoxetine tablets (60 mg). This new approval opens doors for a cost-effective alternative to the branded antidepressant, enhancing patient access and strengthening Strides Pharma's presence in the competitive US generics market. Dive into the details of this important development and what it means for patients and the pharmaceutical industry.
Strides Pharma Science Ltd has secured USFDA approval for its generic version of Theophylline Extended-Release Tablets, marking a significant milestone for the company. Available in 300 mg and 450 mg strengths, this new generic option offers a cost-effective solution for managing chronic respiratory conditions such as asthma. With this approval, Strides Pharma aims to expand its market presence and provide patients with affordable, high-quality medication alternatives.
Biocon Pharma has secured USFDA approval to market its generic Sacubitril/Valsartan Tablets, available in three strengths: 24 mg/26 mg, 49 mg/51 mg, and 97 mg/103 mg. This milestone is set to offer a cost-effective alternative for treating chronic heart failure, enhancing patient access and expanding Biocon’s market presence. Discover the significance of this approval and its implications for both patients and the pharmaceutical industry.
Zydus Lifesciences Ltd. has achieved a significant milestone with USFDA approval for its Scopolamine transdermal system. This innovative 1 mg/3-day patch is designed to effectively prevent nausea and vomiting, offering a convenient and controlled method of treatment. Discover how this approval enhances Zydus' market position and what it means for patients in need of effective anti-nausea solutions.
Zydus Lifesciences has achieved a major milestone with USFDA approval for Amantadine extended-release capsules, aimed at treating dyskinesia in Parkinson’s disease patients. The company has also received tentative approval for Gocovri capsules, promising more affordable treatment options. Discover how these approvals could enhance access to essential Parkinson's disease therapies.
Zydus Lifesciences has achieved a significant breakthrough with regulatory approval from Mexico for Bhava, a cutting-edge biosimilar targeting multiple cancers. This milestone underscores Zydus Lifesciences' commitment to advancing oncology treatments globally, promising new hope for patients and healthcare providers alike.